文献速递乳腺癌支持与姑息治疗

乳腺癌相关手臂淋巴水肿的前瞻性监测:系统评价与Meta分析

Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Clin Oncol · 2022-01-25

该系统评价与Meta分析纳入23项研究(21项评估乳腺癌相关手臂淋巴水肿),评估前瞻性监测联合早期管理对慢性淋巴水肿的预防效果。两项随机对照试验(N=106)显示,与常规护理相比,参与前瞻性监测联合早期管理可降低慢性乳腺癌相关手臂淋巴水肿风险(RR 0.31;95%CI 0.10-0.95)。15项观察性研究(N=3545)的慢性淋巴水肿合并率为4%(95%CI 3-6),腋窝淋巴结清扫亚组(12项研究,N=1527)为6%(95%CI 4-9)。

要点

  • 前瞻性监测联合早期管理可降低慢性乳腺癌相关手臂淋巴水肿风险(RR 0.31;95%CI 0.10-0.95;2项RCT;N=106)。
  • 观察性研究中慢性乳腺癌相关手臂淋巴水肿合并率为4%(95%CI 3-6;15项研究;N=3545)。
  • 腋窝淋巴结清扫患者慢性淋巴水肿合并率为6%(95%CI 4-9;12项研究;N=1527)。

核心结论

  • 研究结果提示,参与前瞻性监测联合早期管理可降低慢性乳腺癌相关手臂淋巴水肿的风险。
  • 因腋窝手术而处于淋巴水肿高风险的参与者中,仅少数发生慢性淋巴水肿。
  • 需要更稳健的研究来确定前瞻性监测联合早期管理能否降低慢性淋巴水肿风险,尤其是在乳腺癌以外的其他癌症生存者中。

研究设计与样本

  • 系统评价与Meta分析(注册号CRD42019137965),检索5个数据库和2个注册库,截至2021年2月26日。
  • 纳入评估参与前瞻性监测项目相关的淋巴水肿发生率或患病率的随机对照试验或观察性研究。
  • 共纳入23项研究,其中21项评估乳腺癌相关手臂淋巴水肿。
  • 提取触发早期淋巴水肿管理的例数、缓解例数和慢性淋巴水肿例数。
  • 计算慢性淋巴水肿的合并相对风险(试验)和合并率(累积发生率;观察性研究)。

主要发现

  • 与常规护理相比,参与前瞻性监测联合早期管理降低慢性乳腺癌相关手臂淋巴水肿风险(RR 0.31;95%CI 0.10-0.95;2项RCT;N=106)。
  • 慢性乳腺癌相关手臂淋巴水肿合并率为4%(95%CI 3-6;15项观察性研究;N=3545)。
  • 限制于腋窝淋巴结清扫参与者时,慢性乳腺癌相关手臂淋巴水肿合并率为6%(95%CI 4-9;12项研究;N=1527)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更稳健的研究来确定前瞻性监测联合早期管理能否降低慢性淋巴水肿风险,尤其是在乳腺癌以外的其他癌症生存者中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The call to integrate prospective surveillance for lymphedema into cancer care pathways is building momentum to enable early intervention and prevent the progression of the condition. We offer a critical evaluation of the literature on prospective surveillance and early management for cancer-related lymphedema and evaluate the effect of such programs in preventing chronic lymphedema (CRD42019137965). METHODS: Five databases and two registries were searched for randomized controlled trials or observational studies that assessed the incidence or prevalence of lymphedema associated with participation in a prospective surveillance program, published until February 26, 2021. Numbers triggered for early lymphedema management, resolved, and chronic lymphedema were extracted. Pooled relative risk (trials) and pooled rate (cumulative incidence; observational studies) of chronic lymphedema was calculated. Subgroup analyses assessed the effect of study design, length of follow-up, and extent of axillary surgery. RESULTS: Twenty-three studies were included, of which 21 studies evaluated breast cancer-related arm lymphedema (BCRaL). Participation in prospective surveillance with early management reduced the risk of chronic BCRaL versus usual care (relative risk 0.31; 95% CI, 0.10 to 0.95; two randomized controlled trials; N = 106). The pooled rate of chronic BCRaL was 4% (95% CI, 3 to 6; 15 observational studies; N = 3,545), and 6% (95% CI, 4 to 9) when restricted to participants with axillary lymph node dissection (12 studies; N = 1,527). CONCLUSION: The findings suggest that participation in prospective surveillance with early management reduces the risk of chronic BCRaL. Only a minority of patients at high risk of lymphedema because of axillary surgery developed chronic lymphedema. More robust research is needed to determine whether prospective surveillance with early management can reduce the risk of chronic lymphedema, particularly among cancer survivors other than breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rafn BS, Christensen J, Larsen A, et al. Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis. J Clin Oncol. 2022. PMID: 35077194. doi:10.1200/JCO.21.01681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。